Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (201-210 of 337) with videos related to

Pageof 34
Sort By:
The Journal of Biological Chemistry|February 18, 2018
Structural and compositional diversity of fibrillin microfibrils in human tissuesAlexander Eckersley, Kieran T Mellody, Suzanne Pilkington, et al.
The Journal of Investigative Dermatology|May 13, 2026
A survey of patients attending the Regional Dermatology Training Centre, Moshi, Tanzania 2017-2020Aakaash Varma, Lakshaajeni Thevapalan, Doriane Sabushimike, et al.
Journal of the American Academy of Dermatology|July 4, 2018
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 studyCarle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, et al.
The Journal of Investigative Dermatology|June 12, 2004
Divergent beliefs about psoriasis are associated with increased psychological distressHelen L Richards, Dónal G Fortune, Stephanie L P Chong, et al.
Scientific Reports|December 15, 2022
Menopause induces changes to the stratum corneum ceramide profile, which are prevented by hormone replacement therapyAlexandra C Kendall, Suzanne M Pilkington, Jonathan R Wray, et al.
The Gerontologist|March 20, 2016
Age-Associated Skin Conditions and Diseases: Current Perspectives and Future OptionsUlrike Blume-Peytavi, Jan Kottner, Wolfram Sterry, et al.
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Redox Biology|April 28, 2015
A potential role for endogenous proteins as sacrificial sunscreens and antioxidants in human tissuesSarah A Hibbert, Rachel E B Watson, Neil K Gibbs, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 11, 2023
Implementing well-being in the management of psoriasis: An expert recommendationRachel Sommer, Ulrich Mrowietz, Kristian Gaarn Du Jardin, et al.
Pageof 34

Showing results (201-210 of 337) with videos related to

Sort By:
Pageof 34
The Journal of Biological Chemistry|February 18, 2018
Structural and compositional diversity of fibrillin microfibrils in human tissuesAlexander Eckersley, Kieran T Mellody, Suzanne Pilkington, et al.
The Journal of Investigative Dermatology|May 13, 2026
A survey of patients attending the Regional Dermatology Training Centre, Moshi, Tanzania 2017-2020Aakaash Varma, Lakshaajeni Thevapalan, Doriane Sabushimike, et al.
Journal of the American Academy of Dermatology|July 4, 2018
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 studyCarle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, et al.
The Journal of Investigative Dermatology|June 12, 2004
Divergent beliefs about psoriasis are associated with increased psychological distressHelen L Richards, Dónal G Fortune, Stephanie L P Chong, et al.
Scientific Reports|December 15, 2022
Menopause induces changes to the stratum corneum ceramide profile, which are prevented by hormone replacement therapyAlexandra C Kendall, Suzanne M Pilkington, Jonathan R Wray, et al.
The Gerontologist|March 20, 2016
Age-Associated Skin Conditions and Diseases: Current Perspectives and Future OptionsUlrike Blume-Peytavi, Jan Kottner, Wolfram Sterry, et al.
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Redox Biology|April 28, 2015
A potential role for endogenous proteins as sacrificial sunscreens and antioxidants in human tissuesSarah A Hibbert, Rachel E B Watson, Neil K Gibbs, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 11, 2023
Implementing well-being in the management of psoriasis: An expert recommendationRachel Sommer, Ulrich Mrowietz, Kristian Gaarn Du Jardin, et al.
Pageof 34